Innovations In Clinical Neuroscience

SEP-OCT 2014

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/425963

Contents of this Issue

Navigation

Page 75 of 201

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 1 , N U M B E R 9 – 1 0 , S E P T E M B E R – O C T O B E R 2 0 1 4 ] 76 T ABLE 4. Possible combinations of suicidal Ideation and missing combinations between the C–SSRS and the FDA-CASA 2012 based on category titles, definitions, and probe questions P ossible C ombination N umber Passive Ideation Active Ideation M ethod I ntent P lan C ombinations Not Captured By FDA-CASA 2012 T itles C ombinations Not Captured By FDA-CASA 2012 D efinitions C ombinations N ot Captured By C –SSRS Titles C ombinations Not Captured By C–SSRS D efinitions C ombinations Not Captured By C–SSRS Probe Q uestions Do the FDA-CASA 2012 T itles & Definitions and the C –SSRS Titles, Definitions, & Probe Questions ALL Capture This Combination? 1 0 0 0 0 0 Yes 2 0 1 0 0 0 Yes 3 0 0 0 1 0 3 3 3 3 3 O verlooked 4 0 1 0 1 0 3 N o 5 0 0 1 0 0 3 3 3 3 No 6 0 1 1 0 0 Y es 7 0 0 1 1 0 3 3 3 3 N o 8 0 1 1 1 0 3 3 3 No 9 0 0 0 0 1 3 3 3 3 3 Overlooked 1 0 0 1 0 0 1 3 3 3 3 N o 11 0 0 0 1 1 3 3 3 3 3 Overlooked 12 0 1 0 1 1 3 No 13 0 0 1 0 1 3 3 3 3 No 14 0 1 1 0 1 3 3 3 3 No 15 0 0 1 1 1 3 3 3 3 No 16 0 1 1 1 1 3 3 3 No 17 1 0 0 0 0 Yes 18 1 1 0 0 0 3 3 3 3 No 19 1 0 0 1 0 3 3 3 3 No 20 1 1 0 1 0 3 3 3 3 No 21 1 0 1 0 0 3 3 3 3 No 22 1 1 1 0 0 3 3 3 3 No 23 1 0 1 1 0 3 3 3 3 No 24 1 1 1 1 0 3 3 3 3 No 25 1 0 0 0 1 3 3 3 3 No 26 1 1 0 0 1 3 3 3 3 No 27 1 0 0 1 1 3 3 3 3 No 28 1 1 0 1 1 3 3 3 3 No 29 1 0 1 0 1 3 3 3 3 No 30 1 1 1 0 1 3 3 3 3 No 31 1 0 1 1 1 3 3 3 3 No 32 1 1 1 1 1 3 3 3 3 No Total 32 26 26 26 26 3 Yes: 4 of 32; No: 25 of 32; Overlooked: 3 of 32 Note 1: This table summarizes most of the other tables into one. If the titles, definitions, and probe questions were consistent within the C–SSRS titles, definitions, and probe questions and consistent within the FDA-CASA 2012 titles and definitions, then the check marks in the columns titled "Combinations Not Captured…" should be consistent across every row. But they are not. Note 2: There are ambiguities within the components of the FDA-CASA 2012 title, within the components of the FDA-CASA 2012 definition, within the components of the C-SSRS title, within the components of the C–SSRS definition, and within the components of the C–SSRS probe questions, and further ambiguities between the wording across the titles, definitions, and probe questions. This table ignores the ambiguities within the components of the titles, definitions, and probe questions and uses the best case scenario for interpretation. C–SSRS: Columbia–Suicide Severity Rating Scale; FDA-CASA 2012: United States Food and Drug Administration-Classification Algorithm for Suicide Assessment

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - SEP-OCT 2014